Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data

• Hoofdauteurs: Ekaterina Alexeeva (Auteur), Elizaveta Krekhova (Auteur), Tatyana Dvoryakovskaya (Auteur), Ksenia Isaeva (Auteur), Aleksandra Chomakhidze (Auteur), Evgeniya Chistyakova (Auteur), Olga Lomakina (Auteur), Rina Denisova (Auteur), Anna Mamutova (Auteur), Anna Fetisova (Auteur), Marina Gautier (Auteur), Dariya Vankova (Auteur), Ivan Kriulin (Auteur), Ruslan Saygitov (Auteur)
• Formaat: Boek
• Gepubliceerd in: Frontiers Media S.A., 2023-02-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

BackgroundA significant number of systemic juvenile idiopathic arthritis (sJIA) patients discontinue biologic disease-modifying antirheumatic drugs (bDMARDs) due to lack of efficacy or safety concerns. Studies of biologic therapy switch regimens in sJIA are required.MethodsPatients with sJIA who swi...